Across TCGA pan-cancer cohorts, TP73-AS1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TP73-AS1 data layer compared with 18 for mass-spec protein.
The strongest signal is observed in rectum adenocarcinoma (READ), where higher TP73-AS1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TP73-AS1 expression acts as an unfavorable survival marker.
READ and LUSC are the cancer types where TP73-AS1 Mutation most reproducibly stratifies survival.